Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
Metrics: PDF 586 views | ?
1 Haematopathology Laboratory, ACTREC, Tata Memorial Centre, Navi Mumbai, India
2 Adult Haematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India
3 Biostatistics, ACTREC, Tata Memorial Centre, Navi Mumbai, India
4 Dept of Cytogenetics, ACTREC, Tata Memorial Centre, Navi Mumbai, India
5 Homi Bhabha National Institute, Training School Complex, Mumbai, India
6 Haemato-Oncology, CyteCare Cancer Hospital, Bangalore, India
* These authors contributed equally to this work
Published: January 15, 2019
This article has been corrected: The correct Funding information is given below:
This work was supported by the Wellcome Trust/DBT India Alliance Fellowship [grant number IA/CPHI/14/1/501485] awarded to Dr Nikhil Patkar. Initial part of the study (8 colour FCM) was funded by a Lady Tata Memorial Trust Grant awarded to Prof Navin Khattry.
Original article: Oncotarget. 2018; 9:36613-36624. DOI: https://doi.org/10.18632/oncotarget.26400.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.